Comparative Effectiveness of a Second Tumor Necrosis Factor Inhibitor Versus a Non-Tumor Necrosis Factor Biologic in the Treatment of Patients With Polyarticular-Course Juvenile Idiopathic Arthritis.
Melissa L MannionShahla AminStephen J BalevicMin-Lee ChangColleen K CorrellLianne Kearsley-FleetKimme L HyrichTimothy Beukelmannull nullPublished in: Arthritis care & research (2024)
Most patients with pJIA started receiving TNFi rather than non-TNFi as their second biologic, and there were no differences in disease activity at six months.